SVETLANA AGAPOV: Open Payments
NPI 1952088668 · LEWES, DE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,371 in 63 payments from 16 companies in 2025. Trend: 2023 $354 · 2024 $926 · 2025 $1,371
Food & beverage: $1,371
| Company | Payments | Amount |
|---|---|---|
| PFIZER INC. | 15 | $252 |
| Amgen Inc. | 9 | $238 |
| Novartis Pharmaceuticals Corporation | 12 | $214 |
| Novo Nordisk Inc | 3 | $148 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | 4 | $105 |
| AstraZeneca Pharmaceuticals LP | 4 | $91 |
| SCPHARMACEUTICALS INC. | 4 | $82 |
| Merck Sharp & Dohme LLC | 3 | $64 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $43 |
| Vital Connect, Inc | 1 | $26 |
Products named: REPATHA, LEQVIO, ELIQUIS, Ozempic, VYNDAQEL, LifeVest, FUROSCIX, VERQUVO.
Industry payments across DE — which companies pay providers there.
